Group Members

Abdul Hamid Salman AnwarM. Yaqoob S M OwaisMadiha MushtaqMadiha Noor QuratulenFarukh ShareefAsmara

IntroductionFounded in 1896 by Fritz Hoffman-La Roche.Headquarters are in Basel Switzer Land.3rd largest Company all over the world.Operates in 6 regions of the world.

Vision“Strengthen our leading position in diagnostics and

shape the health information market by integrating test results and medical information to

support medical decision-makers and superior patient management.”

MissionOur aim as a leading healthcare company is to create, produce, and market innovative solutions of high quality for unmet medical needs. Our mission is to create added value in healthcare by focusing on our expertise in Diagnostics and Pharmaceuticals. We aim to improve patient care by discovering, developing, manufacturing, and marketing innovative, high quality, cost-effective healthcare products and services.

Proposed VisionTo be the number 1 and most admired

Health Care Company in the world.

Proposed MissionModified Mission Statement:

To deliver consistently superior products and services globally and nationally through combination of R&D ( advanced technology) and positive workforce, which contribute significantly to improving the quality of life for consumers.

GapsMarketTechnologyEmployees

HEIRARCHY

Roche Employees

Key Facts of Roche

Pipe Line Products

STAGE 1 : INPUT STAGEExternal Factor Evaluation Matrix (EFE)      

Opportunities Weight Rating Weighted Score

Zarb-e-azab 0.05 3 0.15

Operation against corruption 0.04 2 0.08

66 New molecules are in Pipeline 0.07 4 0.28

Roche also working on rare disease 0.07 4 0.28

Personalized health care introduce in Pakistan and other countries.

0.03 3 0.09

Strategic opportunities may arise from Health IT and Big Data system of Roche

0.03 4 0.12

‘Bhatta-Khori’ is lesser day by day which help Roche to increase profit margin

0.06 3 0.18

Developing innovative approaches in collaboration with international and local players

0.05 4 0.20

Roche make the strategic planning with African govt. and stakeholders for the availability of the innovative medicine.

0.03 2 0.06

Ranking of Roche is 5th among the Pharmaceuticals in world wide.

0.07 4 0.28

Threats Weight Rating Weighted Score

Law and order situation. 0.06 3 0.18

R& D therats 0.08 4 0.32

Smuggling of medicine 0.06 4 0.24

Sustainability risk identified in 2014 report is cyber-attacks, Third party relationship, inadequate strategies for Cloud, m-Health (use of mobile devices), e-Health (Use of electronic Devices and Social media.

0.02 2 0.04

Imitation of products/ fake medicines supplied under brands name can affect brand

0.05 3 0.15

Fluctuation in dollar rates 0.04 3 0.12

Avastin receives negative response from the FDA for use in breast cancer treatment.

0.03 2 0.06

Regulatory environment is becoming more & more stringent 0.04 3 0.12

Hard to forecast external factors 0.07 4 0.28

loss of patent protection in developing countries 0.05 4 0.20

TOTALS 1.00   3.43

COMPETITIVE PROFILE MATRIXCompetitive Profile Matrix (CPM)

  Roche Abbott Sanofi

Critical Success Factors Weight

Rating

Score

Rating

Score

Rating

Score

Advertising 0.03 1 0.03 2 0.06 1 0.03Market Penetration 0.08 3 0.24 4 0.32 3 0.24Marketing 0.02 1 0.02 2 0.04 1 0.02Distribution Channels 0.13 3 0.39 3 0.39 3 0.39R&D 0.14 4 0.56 4 0.56 2 0.28Employee Dedication 0.07 3 0.21 2 0.14 3 0.21Financial Profit 0.08 3 0.24 3 0.24 2 0.16Customer Loyalty 0.09 3 0.27 2 0.18 3 0.27Market Share 0.09 3 0.27 3 0.27 4 0.36Product Quality 0.11 4 0.44 4 0.44 4 0.44Top Management 0.06 2 0.12 3 0.18 2 0.12Profit Margin 0.10 4 0.40 2 0.20 3 0.30

Totals 1.00   3.19   3.02   2.82

INTERNAL FACTOR EVALUATION

Strengths Weight Rating Avg. Weighted  

Global presence 0.03 4 0.12Providing high quality products 0.02 4 0.08Efficient Management 0.08 4 0.32Strategic Alliance and acquisitions 0.07 3 0.21Patents 0.01 3 0.03Diversified portfolio 0.02 3 0.06Human resource 0.07 4 0.28Continuous Improvements 0.06 3 0.18Strong research and development 0.01 4 0.04Weakness      Distribution channel 0.03 2 0.06Labor turnover 0.05 1 0.05Decreasing market share 0.04 2 0.08Internal control system 0.03 2 0.06Lack of wide range of products 0.03 2 0.06Threats of new entrants 0.09 2 0.18Lack of wide area space 0.16 2 0.32Less promotional and advertisement 0.2 2 0.4Total weighted score 1   2.53

STAGE# THE MATCHING STAGE

SWOT AnalysisSTRENGTH1. Roche Pakistan is 42% share and global share is about 28%2. Brand heritage is high3. Roche have very strong distribution network 4. 81% of the employee are proud to work with Roche.5. Roche Pakistan is leading brand of glucometer .i.e. Accu-

Chek and it is present in Pakistan since last 20 years it almost cover the 45% market of Glucometer in Pakistan

6. It is no # 1 in Biotech, Oncology, diagnostic and hospital marketing. In Pakistan and world wide

7. World most sustainable company in life sciences 8. Continuous product development9. 4% Increase in Pharmaceutical sales from last year

worldwide.10. SHE safety, Security and environmental Protection is the

integral part of Roche operations

WEAKNESS1. No local production. Roche products are imported so import

cost is higher than the local production 2. Lack of coordination between industry and academia3. No ATL activities .Roche is mostly involve in BTL activity.4. Lack of infrastructure5. Un-trained trained professionals 6. Lack of affordability 7. High internal pressure of cost adversely affects the

developmental activities.

OPPORTUNITY1. Zarb-e-azb in Pakistan2. Operation against corruption in Pakistan.3. 66 New molecules are in Pipeline >30 cancer medicine

are in clinical development4. Roche also working on rare disease 5. Bhatta-Khori’ is lesser day by day which help Roche to

increase profit margin.6. developing innovative approaches in collaboration with

international and local players 7. Ranking of Roche is 3rd among the Pharmaceuticals in

world wide. Roche ranks world’s leading health care with two core expertise that is diagnostic and Pharmaceuticals.

8. Strategic opportunities may arise from Health IT and Big Data system of Roche.

9. Roche make the strategic planning with African govt. and stakeholders for the availability of the innovative medicine.

10. Personalized health care introduce in Pakistan and other countries.

THREATS1. Law and order situation. 2. R & D threats3. Smuggling of medicine 4. Sustainability risk identified in 2014 report is cyber-

attacks, Third party relationship, inadequate strategies for Cloud, m-Health (use of mobile devices), e-Health (Use of electronic Devices and Social media.

5. Imitation of products/ fake medicines supplied under brands name can affect brand.

6. Fluctuation in dollar rates

7. Avastin receives negative response from the FDA for use in breast cancer treatment.

8. Regulatory environment is becoming more & more stringent

9. Lose of patent protection in developing countrieS

10. Hard to forecast external factors

SWOT STRATEGIESSO 1.Penetration in KPK & Baluchistan .(S1,O1)2. Penetration to other markets internationally (S1,O9)3. New Product development in collaboration with international and local players (S3, O6)

WO1.New Infrastructure for local production (W4,O2)2. Training of employees (W5,O7)WT1.Inovolve academia for the development of new product development (W2,T7)2.More research for epidemics and new illness by involving academia and continuous research to reduce the cost of production (W2,T2,T8)ST1.Investment in continous product development (S8,T2)2.Investment for the protection of cyber-attacks (S9,T4)

SPACE MATRIXInternal Analysis:         External Analysis:          Financial Position (FP)       Stability Position (SP)        Return on Investment (ROI) 5 Rate of Inflation   -3Leverage 5 Technological Changes   -1Liquidity 4 Price Elasticity of Demand   -3Working Capital 4 Competitive Pressure   -3Net Income 4 Barriers to Entry into Market   -2                             Financial Position (FP) Average 4.4 Stability Position (SP) Average   -2.4

Internal Analysis:         External Analysis:          Competitive Position (CP)     Industry Position (IP)        Market Share -1 Growth Potential   5Product Quality -1 Financial Stability   6Customer Loyalty -2 Ease of Entry into Market   3Technological know-how -1 Resource Utilization   6Control over Suppliers and Distributors -2 Profit Potential   5                   Competitive Position (CP) Average -1.4 Industry Position (IP) Average     5.0

SPACE MATRIX

Grand Strategy Matrix          Rapid Market Growth                                                Quadrant II         Quadrant I                                                                          0                                     0                                                                                                     

                           

Weak Competitive

Position

                   Strong

Competitive Position

                                                         

                                                                                     0                      

                  Roche                                                                                             Quadrant III         Quadrant IV                                   Slow Market Growth                       

BCG MATRIXCobas e 602 (2797

m)Accu Check Aviva

(2159 m)

Cobas 6800 (530 m)

Kadsayla ( 536 m)

Accu Chek Advantage

Pegesus

Avasting (6417 m)

Hercepting (6274 m)

THIRD STAGE:DECISION STAGE

QSPM

   

KPK Penetration Better employee programs to heighten

perceived Value of salary, benefits, and self recognition

   

   Opportunities Weight AS TAS AS TASZarb-e-azab 0.05 4 0.20 2 0.10Operation against corruption 0.04 2 0.08 3 0.1266 New molecules are in Pipeline 0.07 3 0.21 3 0.21Roche also working on rare disease 0.08 3 0.24 3 0.24

Personalized health care introduce in Pakistan and other countries. 0.03 4 0.12 4 0.12

Strategic opportunities may arise from Health IT and Big Data system of Roche0.03 3 0.09 4 0.12

‘Bhatta-Khori’ is lesser day by day which help Roche to increase profit margin0.06 4 0.24 3 0.18

Developing innovative approaches in collaboration with international and local players 0.05 4 0.20 3 0.15

Roche make the strategic planning with African govt. and stakeholders for the availability of the innovative medicine. 0.03 2 0.06 3 0.09

Roche's partnership with local companies in India and China to commercialize its drug Tamiflu.0.06 2 0.12 3 0.18

Threats Weight AS TAS AS TASLaw and order situation. 0.06 3 0.18 3 0.18R& D therats 0.08 3 0.24 3 0.24Smuggling of medicine 0.06 4 0.24 3 0.18Sustainability risk identified in 2014 report is cyber-attacks, Third party relationship, inadequate strategies for Cloud, m-Health (use of mobile devices), e-Health (Use of electronic Devices and Social media. 0.02 3 0.06 3 0.06

Imitation of products/ fake medicines supplied under brands name can affect brand0.05 4 0.20 3 0.15

Fluctuation in dollar rates 0.04 2 0.08 2 0.08Avastin receives negative response from the FDA for use in breast cancer treatment.

0.03 3 0.09 3 0.09

Regulatory environment is becoming more & more stringent 0.04 3 0.12 4 0.16Hard to forecast external factors 0.07 3 0.21 3 0.21loss of patent protection in developing countries 0.05 2 0.10 2 0.10

   

Penetration in KPKBetter employee programs to heighten

perceived Value of salary, benefits, and self

recognition

   

   Strengths Weight AS TAS AS TAS1. Roche Pakistan is 42% share and global share is about 28% Brand

0.06 3 0.18 3 0.18

Brand heritage is high 0.07 3 0.21 4 0.28Roche have very strong distribution network 0.06 4 0.24 4 0.2481% of the employee are proud to work with Roche. 0.05 4 0.20 4 0.205. Roche Pakistan is leading brand of glucometer .i.e. Accu-Chek and it is present in Pakistan since last 20 years it almost cover the 45% market of Glucometer in Pakistan

0.05 3 0.15 3 0.15

It is no # 1 in Biotech, Oncology, diagnostic and hospital marketing.0.05 3 0.15 3 0.15

World most sustainable company in life sciences 0.03 3 0.09 3 0.09 Continuous product development 0.04 1 0.04 2 0.084% Increase in Pharmaceutical sales from last year worldwide. 0.06 3 0.18 3 0.18SHE safety, Security and environmental Protection is the integral part of Roche operations

0.03 2 0.06 2 0.06

Weaknesses Weight AS TAS AS TASNo local production. 0.05 3 0.15 2 0.10Lack of coordination between industry and academia 0.06 0 0.00 1 0.06No ATL activities .Roche is mostly involve in BTL activity. 0.04 2 0.08 2 0.08Lack of infrastructure 0.06 4 0.24 4 0.24Un-trained trained professionals

0.05 2 0.10 3 0.15

Lack of affordability 0.05 3 0.15 1 0.05High internal pressure of cost adversely affects the developmental activities.

0.04 2 0.08 1 0.04

Roche products are imported, so import cost is higher than the local production 0.04 2 0.08 2 0.08

Lack of Promotional Campaign. 0.06 2 0.12 2 0.12Lack of R& D in Pakistan 0.05 4 0.20 4 0.20

TOTALS     5.78   5.69

Recommendations:

• Technological Advancements • Research and Development• Market penetration • Product Development.• Customer Care.